Epstein-Barr virus oncogenesis

Critical Reviews in Oncology/Hematology

Volumn 26, Issue 2, 1997, Pages 117-135

  Knecht, Hans ^a   Berger, Christoph ^a   Al Homsi, A Samer ^a   McQuain, Catherine ^a   Brousset, Pierre ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS PROTEIN;

BURKITT LYMPHOMA; CARCINOGENESIS; EPSTEIN BARR VIRUS; HUMAN; NONHUMAN; PROMOTER REGION; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; PROTEIN STRUCTURE, SECONDARY; TUMOR CELLS, CULTURED; TUMOR VIRUS INFECTIONS; VIRAL MATRIX PROTEINS;

EID: 0030753706     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)00016-4     Document Type: Review

References (263)

1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964;702-703.
2. Burkitt D. Long-term remissions following one and two-dose chemotherapy for African lymphoma. Cancer 1967;20:756-9.
3. Henle G, Henle W, Diehl V. Relation of burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA 1968;59:94-101.
4. zur Hausen H, Schulte-Holthausen H, Klein G, et al. EBV DNA in biospies of Burkitt tumours anaplastic carcinomas of the nasopharynx. Nature 1970;228:1056-8.
5. Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM et al., editors. Fundamental Virology. Philadelphia: Lippincott-Raven, 1996:1109-1163.
6. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM et al., editors. Fields Virology. Philadelphia: Lippincott-Raven, 1996:2397-2446.
7. Gratama JW, Ernberg I. Molecular epidemiology of Epstein-Barr virus infection. Adv Cancer Res 1995;67:197-255.
8. Magrath I, Jain V, Bhatia K. Epstein-Barr virus and Burkitt's lymphoma. Semin Cancer Biol 1992;3:285-95.
9. Rickinson AB, Murray RJ, Brooks J. T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv 1992;13:53-80.
10. Wilson JB, Levine AJ. The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice. Curr Top Microbiol Immunol 1992;182:375-84.
11. Pallesen G, Hamilton-Dutoit SJ, Zhou X. The association of Epstein-Barr virus (EBV) with T cell proliferations and Hodgkin's disease: two new developments in the EBV field. Adv Cancer Res 1993;62:179-239.
12. Straus SE, Cohen JI, Tosato G, et al. Epstein-Barr virus infections: Biology, pathogenesis and management. Ann Intern Med 1993;118:45-58.
13. Joske DJL, Knecht H. Epstein-Barr virus in lymphomas: a review. Blood Rev 1993;7:215-22.
14. + malignant lymphomas. Crit Rev Oncogenesis 1993;4:191-239.
15. Knecht H, Brousset P, Bachmann E, et al. Latent membrane protein 1: a key oncogene in EBV-related carcinogenesis. Acta Haematol 1993;90:167-71.
16. Henderson SA, Huen D, Rowe M. Epstein-Barr virus transforming proteins. Semin Virol 1994;5:391-9.
17. Khanna R, Burrows SR, Moss DJ. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev 1995;59:387-405.
18. Farrell PJ. Epstein-Barr virus immortalizing genes. Trends Micro 1995;3:105-9.
19. Dreyfus DH, Kelleher CA, Jones JF, et al. Epstein-Barr virus infection of T cells: Implications for altered T-lymphocyte activation, repertoire development and autoimmunity. Immunol Rev 1996;152:89-110.
20. Weiss LM, Chang KL. Association of the Epstein-Barr virus with hematolymphoid neoplasia. Adv Anatom Pathol 1996;3:1-15.
21. Jenkins PJ, Farrell PJ. Are particular Epstein-Barr virus strains linked to disease?. Cancer Biol 1996;7:209-15.
22. Berger C, Brousset P, McQuain C, Knecht H. Deletion variants within the NF-κB activation domain of the LMP1 oncogene in acquired immunodeficiency syndrome-related large cell lymphomas, in prelymphomas and atypical lymphoproliferations. Leukemia Lymphoma 1997 (in press).
23. Tanner J, Weis J, Fearon D, et al. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates absorption, capping, and endocytosis. Cell 1987;50:203-13.
24. Hurley EA, Thorley-Lawson DA. B cell activation and the establishment of Epstein-Barr virus latency. J Exp Med 1988;168:2059-75.
25. Lawrence JB, Villnave CA, Singer RH. Sensitive, high-resolution chromatin and chromosome mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma line. Cell 1988;52:51-61.
26. Hurley EA, Agger S, McNeil JA, et al. When Epstein-Barr virus persistently infects B-cell lines, it frequently integrates. J Virol 1991;65:1245-54.
27. Kelleher CA, Kaufman Paterson R, Dreyfus DH, et al. Epstein-Barr virus replicative gene transcription during de novo infection of human thymocytes: simultaneous early expression of BZLF-1 and its repressor RAZ. Virology 1995;208:685-95.
28. Kaufman Paterson RL, Kelleher C, Amankonah TD, et al. Model of Epstein-Barr virus infection of human thymocytes: Expression of viral genome and impact on cellular receptor expression in the T-lymphoblastic cell line. HPB-ALL. Blood 1995;85:456-64.
29. Young LS, Dawson CW, Brown KW, et al. Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes. Int J Cancer 1989;43:786-94.
30. Birkenbach M, Tong X, Bradbury LE, et al. Characterization of an Epstein-Barr virus receptor on human epithelial cells. J Exp Med 1992;176:1405-14.
31. Sixbey JW, Yao QY. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science 1992;255:1578-80.
32. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986;47:883-9.
33. Baer R, Bankier AT, Biggin MD, et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984;310:207-11.
34. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985;313:812-5.
35. Lupton S, Levine AJ. Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells. Mol Cell Biol 1985;5:2533-42.
36. Hammerschmidt W, Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 1989;340:393-7.
37. Cohen JI, Wang F, Mannick J, et al. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA 1989;86:9558-62.
38. Tomkinson B, Robertson E, Kieff E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 1993;67:2014-25.
39. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993;90:9150-4.
40. Middleton T, Gahn TA, Martin JM et al. Immortalizing genes of Epstein-Barr virus. Adv Virus Res 1991;19-55.
41. Bankier AT, Deininger PL, Satchwell SC, et al. DNA sequence analysis of the EcoRI Dhet fragment of B95-8 Epstein-Barr virus containing the terminal repeat sequences. Mol Biol Med 1983;1:425-45.
42. Fennewald S, van Santen V, Kieff E. Nucleotide sequence of a mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol 1984;51:411-9.
43. Hudson GS, Farrell PJ, Barrell BG. Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95-8. J Virol 1985;53:528-35.
44. Laux G, Economou A, Farrell PJ. The terminal protein gene 2 of Epstein-Barr virus is transcribed from a bidirectional latent promoter region. J Gen Virol 1989;70:3079-84.
45. Gilligan K, Sato H, Rajadurai P, et al. Novel transcription from the Epstein-Barr virus terminal Eco RI fragment DIJhet, in a nasopharyngeal carcinoma. J Virol 1990;64:4948-56.
46. Liebowitz D, Wang D, Kieff E. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol 1986;58:233-7.
47. Hennessy K, Fennewald S, Hummel M, et al. A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc Natl Acad Sci USA 1984;81:7207-11.
48. Knecht H, Bachmann E, Brousset P, et al. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993;82:2937-42.
49. Baichwal VR, Sugden B. Posttranslational processing of an Epstein-Barr virus encoded membrane protein expressed in cells transformed by Epstein-Barr virus. J Virol 1987;61:866-75.
50. Martin J, Sugden B. The latent membrane protein oncoprotein resembles growth factor receptors in the properties of its turnover. Cell Growth Differentiation 1991;2:553-600.
51. Moorthy R, Thorley-Lawson DA. Processing of the Epstein-Barr virus-encoded latent membrane protein p63/LMP. J Virol 1990;64:829-37.
52. Moorthy RK, Thorley-Lawson DA. Biochemical, genetic, and functional analyses of the phosphorylation sites on the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1. J Virol 1993;67:2637-45.
53. Mann KP, Staunton D, Thorley-Lawson DA. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol 1985;55:710-20.
54. Rowe M, Evans HS, Young LS, et al. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J Gen Virol 1987;68:1575-86.
55. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831-40.
56. Baichwal VR, Sugden B. Transformation of Ba1b 3T3 cells by the BNLF-1 gene of Epstein Barr virus. Oncogene 1988;2:461-7.
57. Wilson JB, Weinberg W, Johnson R, et al. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyerplasia and aberrant expression of Keratin 6. Cell 1990;61:1315-27.
58. Fahraeus R, Rymo L, Rhim JS, et al. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 1990;345:447-9.
59. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990;344:777-80.
60. Hammerschmidt W, Sugden B, Baichwal VR. The transforming domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels. J Virol 1989;63:2469-75.
61. Wang D, Liebowitz D, Wang F, et al. Epstein-Barr latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 1988;62:4173-84.
62. Baichwal VR, Sugden B. The multiple membraine-spanning segments of the BNLF-1 oncogene from Epstein-Barr virus are required for transformation. Oncogene 1989;4:67-74.
63. Martin J, Sugden B. Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association. J Virol 1991;65:3246-58.
64. Moorthy RK, Thorley-Lawson DA. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of Rat-1 fibroblasts. J Virol 1993;67:1638-46.
65. Kaye KM, Izumi KM, Mosialos G, et al. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol 1995;69:675-83.
66. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: cell-type-independent-induction of CD23, CD21, and ICAM-1. Leukemia 1993;7:104-12.
67. Huen DS, Henderson SA, Croom-Carter D, et al. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549-60.
68. Peng-Pilon M. Ruuth K, Lundgren E, et al. The cytoplasmic C-terminal domain but not the N-terminal domain of latent membrane protein 1 of Epstein-Barr virus is essential for B cell activation. J Gen Virol 1995;76:767-77.
69. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 1992;7:1775-82.
70. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-15.
71. Finke J, Fritzen R, Ternes P. et al. Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes. Blood 1992;80:459-69.
72. Martin JM, Veis D, Korsmeyer SJ, et al. Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2. J Virol 1993;67:5269-78.
73. Rowe M, Peng-Pilon M, Huen DS, et al. Upregulation of bcl-2 by the Epstein-Barr Virus Latent Membrane Protein LMP1: a B-cell specific response that is delayed relative to NF-κB activation and to induction of cell surface markers. J Virol 1994;68:5602-12.
74. Walter J, Schirrmacher V, Mosier D. Induction of CD44 expression by the Epstein-Barr virus latent membrane protein LMP1 is associated with lymphoma dissemination. Int J Cancer 1995;61:363-9.
75. Monroe JE, Calender A, Mulder C. Epstein-Barr virus-positive and -negative B-cell lines can be infected with human immunodeficiency virus types 1 and 2. J Virol 1988;62:3497-500.
76. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994;12:141-79.
77. Heron E, Deloukas P, van Loon APGM. The complete exonintron structure of the 156-Kb human gene NFKB1, which encodes the p 105 and p50 proteins of transcription factors NF-κB and IκB-γ: implications for NF-κB mediated signal transduction. Genomics 1995;30:493-505.
78. Nabel GJ, Verma IM. Proposed NF-κB/IκB family nomenclature. Genes Dev 1993;7:2063.
79. Hammarskjold ML, Simurada MC. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J Virol 1992;66:6496-501.
80. Opipari AW Jr., Hu HM, Yabkowitz R, et al. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem 1992;267:12424-7.
81. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor χ and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc Natl Acad Sci USA 1989;86:2336-40.
82. Laherty CD, Hu HM, Opipari AW, et al. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J Biol Chem 1992;267:24157-60.
83. Herrero JA, Mathew P, Paya CV. LMP-1 activates NF-κB by targeting the inhibitory molecule IκBα. J Virol 1995;69:2168-74.
84. Mitchell T, Sugden B. Stimulation of NF-κB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol 1995;69:2968-76.
85. Rothenberger S, Bachmann E, Berger C, et al. Natural 30 bp and 69 bp deletion variants of the LMP1 oncogene do stimulate NF-κB-mediated transcription. Oncogene 1997;14:2123-6.
86. Knecht H, McQuain C, Martin J, et al. Expression of the LMP1 oncoprotein in the EBV negative Hodgkin's disease cell line L-428 is associated with Reed-Sternberg cell morphology. Oncogene 1996;13:947-53.
87. Gruss H-J, Brach MA, Drexler HG, et al. Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. Cancer Res 1992;52:3353-60.
88. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells II. Continuous cell lines. Leukemia Lymphoma 1994;3:201-25.
89. van de Stolpe A, Caldenhoven E, Stade BG, et al. 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor α-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. J Biol Chem 1994;269:6185-92.
90. Rothe M, Wong SC, Henzel WJ, et al. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994;78:681-92.
91. Cao Z, Xiong J, Takeuchi M, et al. TRAF6 is a signal transducer for interleukin-1. Nature 1996;383:443-6.
92. Regnier CH, Tomasetto C, Moog-Lutz C, et al. Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem 1995;270:25715-21.
93. Takeuchi M, Rothe M, Goeddel DV. Distinct domains for nucelar factor-κB activation and association with tumor necrosis factor signaling proteins. J Biol Chem 1996;271:19935-42.
94. Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80:389-99.
95. Devergne O, Hatzivassiliou E, Izumi KM, et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol Cell Biol 1996;16:7098-108.
96. Ansieau S, Scheffrahn I, Mosialos G, et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor κB activation. Proc Natl Acad Sci USA 1996;93:14053-8.
97. Eliopoulos AG, Dawson CW, Mosialos G, et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 1996;13:2243-54.
98. Miller WE, Mosialos G, Kieff E, et al. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-κB activation. J Virol 1997;71:586-94.
99. Cuomo L, Ramquist T, Trivedi P, et al. Expression of the Epstein-Barr virus (EBV)-encoded membrane protein LMP1 impairs the in vitro growth, clonability and tumorigenicity of an EBV-negative Burkitt lymphoma line. Int J Cancer 1992;51:949-55.
100. Floettmann JE, Ward K, Rickinson AB, et al. Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines. Virology 1996;223:29-40.
101. Fahraeus R, Jansson A, Kicksten A, et al. Epstein-Barr virus encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. Proc Natl Acad Sci USA 1990;87:7390-4.
102. Ghosh D, Kieff E. Cis-acting regulatory elements near the Epstein-Barr virus latent-infection membrane protein transcriptional start site. J Virol 1990;64:1855-8.
103. Fahraeus R, Jansson A, Sjoblom A, et al. Cell phenotype-dependent control of Epstein-Barr virus latent membrane portein 1 gene regulatroy sequences. Virology 1993;195:71-80.
104. Laux G, Dugrillon F, Eckert C, et al. Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes. J Virol 1994;68:6947-58.
105. Fahraeus R, Palmqvist L, Nerdstedt A. et al. Response to cAMP levels of the Epstein-Barr virus EBNA2-inducible LMP1 oncogene and EBNA2 inhibition of a PP1-like activity. EMBO J 1994;13:6041-51.
106. Ling PD, Hsieh JJD, Ruf IK, et al. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBFI. J Virol 1994;68:5375-83.
107. Zimber-Strobl U, Strobl LJ, Meitinger C, et al. Epstein-Barr virus nuclear antigen 2 exerts its transactivation function through interaction with recombination signal binding protein RBP-Jκ, the homologue of Drosophila suppressor of hairless. EMBO J 1994;13:4973-82.
108. Sauder C, Haiss P, Grasser FA, et al. DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. J Gen Virol 1994;75:3067-79.
109. Johannsen E, Koh E, Mosialos G, et al. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by Jk and PU.1. J Virol 1995;69:253-62.
110. Chen ML, Wu RC, Liu ST, et al. Characterization of 5′-upstream sequence of the latent membrane protein 1 (LMP-1) gene of an Epstein-Barr virus identified in nasopharyngeal carcinoma tissues. Virus Res 1995;37:75-84.
111. Rothenberger S, Bachmann E, Knecht H. Molecular and functional analysis of the Epstein-Barr virus LMP1 oncogene promoter in lymphoproliferative diseases. Exp Hematol (in press).
112. Gahn TA, Sugden B. An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene. J Virol 1995;69:2633-6.
113. Knecht H. Angioimmunoblastic lymphadenopathy: 10 years' experience and state of current knowledge. Semin Hematol 1989;26:208-15.
114. Knecht H, Sahli R, Shaw P, et al. Detection of Epstein-Barr virus DNA by polymerase chain reaction in lymph node biopsies from patients with angioimmunoblastic lymphadenopathy. Br J Haematol 1990;75:610-4.
115. Knecht H, Martius F, Bachmann E, et al. A deletion mutant of the LMP1 oncogene of Epstein-Barr virus is associated with transformation of angioimmunoblastic lymphadenopathy into B-immunoblastic lymphoma. Leukemia 1995;9:458-65.
116. Anagnostopoulos I, Hummel M, Finn T, et al. Heterogenous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angio-immunoblastic lymphadenopathy type. Blood 1992;80:1804-12.
117. Pathmanathan R, Prasad U, Sadler R, et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995;333:693-8.
118. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's diesease: Epidemiologic characteristics in international data. Int J Cancer 1997;70:375-82.
119. Fahraeus R, Fu HL, Ernberg I, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988;42:329-38.
120. Brousset P, Butet V, Chittal S, et al. Comparison of In situ hybridization using different nonisotopic probes for detection of Epstein-Barr virus in nasopharyngeal carcinoma and immunohistochemical correlation with anti-latent membrane protein antibody. Lab Invest 1992;67:457-64.
121. Chang YS, Su IJ, Chung PJ, et al. Detection of an Epstein-Barr-virus variant in T-cell-lymphoma tissues identical to the distinct strain observed in nasopharyngeal carcinoma in the Taiwanese population. Int J Cancer 1995;62:673-7.
122. Raab-Traub N, Rajadurai I, Flynn K, et al. Epstein-Barr virus infection in carcinoma of the salivary gland. J Virol 1991;65:7032-6.
123. Gilligan K, Rajadurai P, Resnick L, et al. Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia. Proc Natl Acad Sci USA 1990;87:8790-4.
124. Sandvej K, Krenacs L, Hamilton-Dutoit SJ, et al. Epstein-Barr virus latent and replicative gene expression in oral hairy leukoplakia. Histopathology 1992;20:387-95.
125. Palefsky JM, Berline J, Penaranda ME, et al. Sequence variation of latent membrane protein-1 of Epstein-Barr virus strains associated with hairy leukoplakia. J Infect Dis 1996;173:710-4.
126. Pallesen G, Hamilton-Dutoit SJ, Rowe M et al., Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991;i:320-322.
127. Herbst H, Dallenbach F, Hummel M, et al. Epstein-Barr virus latent membrane portein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 1991;88:4766-70.
128. Joske DJL, Emery-Goodman A, Odermatt BF, et al. Epstein-Barr virus burden in Hodgkin's disease is related to latent membrane protein gene expression but not to active viral replication. Blood 1992;80:2610-3.
129. Brousset P, Knecht H, Rubin B, et al. Demonstration of Epstein-Barr virus replication in Reed-Sternberg cells of Hodgkin's disease. Blood 1993;82:872-6.
130. Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in malignant cells. J Exp Med 1993; 177:339-49.
131. Weiss LM, Jaffe ES, Liu XF, et al. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 1992;79:1789-95.
132. Chen CL, Sadler RH, Walling DM, et al. Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol 1993;67:6303-8.
133. Korbjuhn P, Anagnostopoulos I, Hummel M, et al. Frequent latent Epstein-Barr virus infection of neoplastic T cells and bystander B cells in human immunodeficiency virus-negative European peripheral pleomorphic T-cell lymphomas. Blood 1993;82:217-23.
134. Sandvej K, Peh SC, Andresen BS, et al. Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: High frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. Blood 1994;84:4053-60.
135. Knecht H, Bachmann E, Brousset P, et al. Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene 1995;10:523-8.
136. Wen S, Mizugaki Y, Shinozaki F, et al. Epstein-Barr virus (EBV) infection in salivary gland tumors: lytic EBV infection in nonmalignant epithelial cells surrounded by EBV-positive T-lymphoma cells. Virology 1997;227:484-7.
137. Herbst H, Dallenbach F, Hummel M, et al. Epstein-Barr virus DNA and latent gene products in Ki-1 (CD30)-positive anaplastic large cell lymphomas. Blood 1991;78:2666-73.
138. Kamel OW, Van de Rijn M, Weiss LM, et al. Reversible lymphomas associated with Epstein-Barr virus occurring during Methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-21.
139. Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al. Expression of Epstein-Barr virus replicative proteins in AIDS-related non-Hodgkin's lymphoma cells. J Pathol 1993;165:289-99.
140. Carbone A, Tirelli U, Gloghini A, et al. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J Clin Oncol 1993;11:1674-81.
141. Thomas JA, Cotter F, Hanby AM, et al. Epstein-Barr virus-related oral T-cell lymphoma associated with human immunodeficiency virus immunosuppression. Blood 1993;81:3350-6.
142. Camilleri-Broet S, Davi F, Feuillard J, et al. High expression of latent membrane protein 1 of Epstein-Barr virus and BCL-2 oncoprotein in acquired immunodeficiency syndrome-related primary brain lymphomas. Blood 1995;86:432-5.
143. Kingma DW, Weiss WB, Jaffe ES, et al. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 1996;88:242-51.
144. Audouin J, Diebold J, Pallesen G. Frequent expression of Epstein-Barr virus latent membrane protein-1 in tumour cells of Hodgkin's disease in HIV-positive patients. J Pathol 1992;167:381-4.
145. Santon A, Manzanal AI, Campo E, et al. Deletions in the Epstein-Barr virus latent membrane protein-1 oncogene in Hodgkin's disease. J Clin Pathol: Mol Pathol 1995;48:M184-7.
146. Bellas C, Santon A, Manzanal A, et al. Pathological, immunological, and molecular features of Hodgkin's disease associated with HIV infection. Am J Surg Pathol 1996;20:1520-4.
147. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989;321:1080-5.
148. Thomas JA, Hotchin NA, Allday MJ, et al. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 1990;49:944-53.
149. Gratama JW, Zutter MM, Minarovits J, et al. Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients. Int J Cancer 1991;47:188-92.
150. Cen H, Williams PA, McWilliams HP, et al. Evidence of restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 1993;81:1393-403.
151. Smir BN, Hauke RJ, Bierman PJ, et al. Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders. Lab Invest 1996;75:575-88.
152. Garnier JL, Lebranchu Y, Dantal J, et al. Hodgkin's disease after transplantation. Transplantation 1996;61:71-6.
153. Anagnostopoulos I, Hummel M, Kreschel C, et al. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 1995;85:744-50.
154. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusion of donor leukocytes to treat Epstein-Barr virus associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;331:679-80.
155. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus related lymphoproliferation. Lancet 1995;345:9-13.
156. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med 1996;2:551-5.
157. Thorley-Lawson DA, Israelsohn ES. Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded P63/latent membrane protein. Proc Natl Acad Sci USA 1987;88:5384-8.
158. Khanna R, Burrows SR, Kurilla MG, et al. Localization of Epstein-Barr virus cytotoxic T cell epitoes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992;176:169-76.
159. Murray RJ, Kurilla MG, Brooks MJ, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992;176:157-68.
160. Lee SP, Thomas WA, Murray RJ, et al. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 1993;67:7428-743.
161. Robertson KD, Manns A, Swinnen LJ, et al. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease. Blood 1996;88:3129-36.
162. Hu LF, Zabarovsky ER, Chen F, et al. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 1991;72:2399-409.
163. Chen ML, Tsai CN, Liang CL, et al. Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 1992;7:2131-40.
164. Hu LF, Chen F, Zheng X, et al. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 1993;8:1575-83.
165. Knecht H, Bachmann E, Joske DJL, et al. Molecular anaylsis of the LMP (latent membrane protein) oncogene in Hodgkin's disease. Leukemia 1993;7:580-5.
166. Berger C, McQuain C, Sullivan JL, et al. The latent membrane protein 1 deletion variant with enhanced oncogenic activity prevails in acute infectious mononucleosis and EBV-associated tonsillar hyperplasia. Blood 1996;88:202a.
167. Li SN, Chang YS, Liu ST. Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene 1996;12:2129-35.
168. Trivedi P, Masucci MG, Winberg G, et al. The Epstein-Barr-virus-encoded membrane protein LMP but not the nuclear antigen EBNA-1 induces rejection of transfected murine mammary carcinoma cells. Int J Cancer 1991;48:794-800.
169. Klein C, Rothenberger S, Niemeyer C, et al. EBV-associated lymphoproliferative syndrome with a distinct 69 base-pair deletion in the LMP-1 oncogene. Br J Haematol 1995;91:938-40.
170. Sandvej K, Munch M, Hamilton-Dutoit S. Mutations in the Epstein-Barr virus latent membrane protein-1 (BNLF-1) gene in spontaneous lymphoblastoid cell lines: effect on in vitro transformation associated parameters and tumorigenicity in SCID and nude mice. J Clin Pathol: Mol Pathol 1996;49:M290-7.
171. Larcher C, McQuain C, Berger C, et al. Epstein-Barr virus associated persistent polyclonal B-cell lymphocytosis with a distinct 69 base pair deletion in the LMP-1 oncogene. Ann Hematol 1997;74:23-8.
172. Knecht H, Raphael M, McQuain C, et al. Deletion variants within the NF-κB activation domain of the LMP1 oncogene prevail in AIDS-related large cell lymphomas and HIV-negative atypical lymphoproliferation. Blood 1996;87:876-81.
173. Vestlev PM, Pallesen G, Sandvej K, et al. Prognosis of Hodgkin's disease is not influenced by Epstein-Barr virus latent membrane protein. Int J Cancer 1992;50:670-1.
174. Hu LF, Chen F, Zhen QF, et al. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur J Can 1995;31A:658-60.
175. Vasef MA, Kamel OW, Chen YY, et al. Detection of Epstein-Barr virus in multiple sites involved by Hodgkin's disease. Am J Pathol 1995;147:1408-15.
176. Brousset P, Schlaifer D, Meggetto F, et al. Persistance of the same viral strain in early and late relapses of Epstein-Barr virus associated Hodgkin's disease. Blood 1994;84:2447-51.
177. Kerr BM, Lear AL, Rowe M, et al. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence on virus promoter usage. Virology 1992;187:189-201.
178. Rowe M, Lear AL, Croom-Carter D, et al. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 1992;66:122-31.
179. Nonkwelo C, Skinner J, Bell A, Rickinson A, Sample J. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1protein. J Virol 1996;70:623-7.
180. Schaefer BC, Strominger JL, Speck SH. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci USA 1995;92:10565-9.
181. Hitt MM, Allday MJ, Hara T, et al. EBV gene expression in an NPC-related tumour. EMBO J 1989;8:2639-51.
182. Brooks L, Yao QY, Rickinson AB, et al. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1 and LMP2 transcripts. J Virol 1992;66:2689-97.
183. Tierney RJ, Steven N, Young LS, et al. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994;68:7374-85.
184. Yates J, Warren N, Reisman D, Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 1984;81:3806-10.
185. Rawlins DR, Milman G, Hayward SD, et al. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 1985;42:859-68.
186. Gahn TA, Schildkraut CL. The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication. Cell 1989;58:527-35.
187. Reisman D, Sugden B. Trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol 1986;6:3838-46.
188. Ambinder RF, Shah WA, Rawlins DR, et al. Definition of the sequence requirements for binding of the EBNA1 protein to its palindromic target sites in Epstein-Barr virus DNA. J Virol 1990;64:2369-79.
189. Shah WA, Ambinder RF, Hayward GS, et al. Binding of EBNA-1 to DNA creates a protease-resistant domain that encompasses the DNA recognition and dimerization functions. J Virol 1992;66:3355-62.
190. Ambinder RF, Mullen MA, Chang YN, et al. Functional domains of Epstein-Barr virus nuclear antigen EBNA1. J Virol 1991;65:1466-78.
191. Chen MR, Middeldorp JM, Hayward SD. Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure. J Virol 1993;67:4875-85.
192. Chen MR, Zong J, Hayward SD. Delineation of a 16 amino acid sequence that forms a core DNA recognition motif in the Epstein-Barr virus EBNA-1 protein. Virology 1994;205:486-95.
193. Snudden DK, Hearing J, Smith PR, et al. EBNA-1, the major nuclear antigen of Epstein-Barr virus, resembles 'RGG' RNA binding proteins. EMBO J 1994;13:4840-7.
194. Sample J, Henson EBD, Sample C, The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated. J Virol 1992;66:4654-61.
195. Jansson A, Masucci M, Rymo L. Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI promoter in Burkitt lymphoma lines. J Virol 1992;66:62-9.
196. Masucci MG, Ernberg I. Epstein-Barr virus: adaptation to a life within the immune system. Trends Microbiol 1994;2:125-30.
197. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995;375:685-8.
198. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, et al. Isolation of Epstein-Barr Virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 1994;68:6069-73.
199. Lenoir GM, Bornkamm GW. Burkitt's lymphoma, a human cancer model for the study of the multistep development of cancer: proposal of a new scenario. In: Klein G, editor. Advances in Viral Oncology 1987;7:173-206.
200. Shiramizu B, Barriga F, Neequaye J, et al. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood 1991;77:1516-26.
201. Miller G. Epstein-Barr virus: biology, pathogenesis and medical aspects. In: Fields BN, Knipe DM, editors. New York: Raven Press, 1990:1921-1958.
202. Razzouk BI, Srinivas S, Sample CE, et al. Epstein-Barr virus DNA recombination and loss in sporadic Burkitt's lymphoma. J Infect Dis 1996;173:529-35.
203. Yancopoulos GD, Blackwell TK, Suh H, et al. Introduced T cell receptor variable region gene segments recombine in pre-B cells: evidence that B and T cells use a common recombinase. Cell 1986;44:251-9.
204. Schatz DG, Oettinger MA, Baltimore D. The V(D)J recombination activating gene, RAG-1. Cell 1989;59:1035-48.
205. Oettinger MA, Schatz DG, Gorka C, et al. RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science 1990;248:1517-23.
206. Knecht H, Joske DJL, Emery-Goodman A, et al. Expression of human recombinase activating genes (RAG-1 and RAG-2) in Hodgkin's disease. Blood 1992;80:2867-72.
207. Kuhn-Hallek I, Sage DR, Stein L. et al. Expression of recombinationm activating genes (RAG-1 and RAG-2) in Epstein-Barr virus-bearing B cells. Blood 1995;85:1289-99.
208. Srinivas S, Sixbey JW. Epstein-Barr virus induction of recombinase-activatinggenes RAG1 and RAG2. J Virol 1995;69:8155-8.
209. Han S, Zheng B, Schatz DG, et al. Neoteny in lymphocytes: Rag1 and Rag2 expression in germinal center B cells. Science 1996;274:2094-7.
210. Liu YJ, Joshua DE, Williams GT, et al. Mechanism of antigen-driven selection in germinal centres. Nature 1989;342:929-31.
211. Liu YJ, de Boutellier O, Guret C, et al. Within germinal centers, isotype switching of immunoglobulin genes occurs after the onset of somatic mutation. Immunity 1996;4:241-50.
212. Bhatia K, Huppi K, Spangler G, et al. Point mutations in the c-myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nature Genetics 1993;5:56-61.
213. Bhatia K, Raj A, Gutierrez MI, et al. Variation in the sequence of Epstein-Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphoma. Oncogene 1996;13:177-81.
214. Niedobitek G, Agathanggelou A, Rowe M, et al. Heterogeneous expression Epstein-Barr virus latent proteins in endemic burkitt's lymphoma. Blood 1995;86:659-65.
215. Carbone A, Gloghini A. Expression of Epstein-Barr virus-encoded latent membrane protein 1 in nonendemic burkitt's lymphomas. Blood 1996;87:1202-3.
216. Rowe M, Rowe DT, Gregory CD, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 1987;6:2743-51.
217. Roth G, Curiel T, Lacy J. Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells. Blood 1994;84:582-7.
218. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992;140:769-74.
219. Selves J, Bibeau F, Brousset P, et al. Epstein-Barr virus latent and replicative gene expression in gastric carcinoma. Histopathology 1996;28:121-7.
220. Oda K, Tamaru J, Takenouchi T, et al. Association of Epstein-Barr virus with gastric carcinoma with lymphoid stroma. Am J Pathol 1993;143:1063-71.
221. Imai S, Koizumi S, Sugiura M, et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA 1994;91:9131-5.
222. Snudden DK, Smith PR, Lai D, et al. Alterations in the structure of the EBV nuclear antigen, EBNA1, in epithelial cell tumours. Oncogene 1995;10:1545-52.
223. Dambaugh T, Hennessy K, Chamnankit L, et al. U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci USA 1984;81:7632-6.
224. Rickinson AB, Young LS, Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA2 on the growth phenotype of virus-transformed B cells. J Virol 1987;61:1310-7.
225. Petti L, Sample C, Kieff E. Subnuclear localization and phosphorylation of Epstein-Barr virus latent infection nuclear proteins. Virology 1990;176:563-74.
226. Rooney C, Howe JG, Speck SH, et al. Influences of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J Virol 1989;63:1531-9.
227. Sinclair AJ, Palmero I, Peters G, Farrell PJ. EBNA-2 and EBNA-LP cooperate to cause G0 and G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J 1994;13:3321-8.
228. Cohen JI, Wang F, Kieff E. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol 1991;65:2545-54.
229. Tong X, Yalamanchili R, Harada S, et al. The EBNA-2 arginine-glycine domain is critical but not essential for B-lymphocyte growth transformation; the rest of region 3 lacks essential interactive domains. J Virol 1994;68:6188-97.
230. Wang F, Gregory C, Sample C, et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 1990;64:2309-18.
231. Cordier M, Calendar A, Billaud M, et al. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol 1990;64:1002-13.
232. Knutson JC. The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. J Virol 1990;64:2530-6.
233. Abbot SD, Rowe M, Cadwallader K, et al. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol 1990;64:2126-34.
234. Wang F, Tsang SF, Kurilla MG, et al. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol 1990;64:3407-16.
235. Zimber-Strobl U, Suentzenich KO, Laux G, et al. Epstein-Barr virus nucelar antigen 2 activates transcription of the terminal protein gene. J Virol 1991;65:415-23.
236. Zimber-Strobl U, Kremmer E, Grasser F, et al. The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter. EMBO J 1993;12:167-75.
237. Sung NS, Kenney S, Gutsch D, et al. EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J Virol 1991;65:2164-9.
238. Scala G, Quinto I, Ruocco MR, et al. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1. J Virol 1993;67:2853-61.
239. Aman P, von Gabain A. An Epstein-Barr virus immortalization associated gene segment interferes specifically with the IFN-induced anti-proliferative response in human B-lymphoid cell lines. EMBO J 1990;9:147-52.
240. Ling PD, Rawlins DR, Hayward SD. The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. Proc Natl Acad Sci USA 1993;90:9237-41.
241. Henkel T, Ling PD, Hayward SD, et al. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein Jκ. Science 1994;265:92-5.
242. Grossman SR, Johannsen E, Tong X, et al. The Epstein-Barr virus nucelar antigen 2 transactivator is directed to response elements by the Jκ recombination signal binding protein. Proc Natl Acad Sci USA 1994;91:7568-72.
243. Waltzer L, Logeat F, Brou C, et al. The human Jκ recombination signal sequence binding protein (RBP-Jκ) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements. EMBO J 1994;13:5633-8.
244. Waltzer L, Bourillot PY, Sergeant A, et al. RBP-Jκ repression activity is mediated by a co-repressor and antagonized by the Epstein-Barr virus transcription factor EBNA2. Nucleic Acid Res 1995;23:4939-45.
245. Hsieh JJD, Henkel T. Salmon P, et al. Truncated mammalian notch1 activates CDF1/RBPJκ-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol 1996;16:952-9.
246. Laux G, Adam B, Strobl LJ, et al. The Spi-1/PU.1 and Spi-B ets family transcription factors and the recombination signal binding protein RBP-Jκ interact with an Epstein-Barr virus nuclear antigen 2 responsive cis-element. EMBO J 1994;13:5624-32.
247. Sixbey JW, Shirley P, Sloas M, et al. A transformation-incompetent, nuclear antigen 2-deleted Epstein-Barr virus associated with replicative infection. J Inf Dis 1991;163:1008-15.
248. Walling DM, Perkins AG, Webster-Cyriaque J, et al. The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression. J Virol 1994;68:7918-26.
249. Schuster V, Ott G, Seidenspinner S, et al. Common Epstein-Barr virus (EBV) type-1 variant strains in both malignant and benign EBV-associated disorders. Blood 1996;87:1579-85.
250. Aitken C, Sengupta SK, Aedes C, et al. Heterogeneity within the Epstein-Barr virus nuclear antigen 2 gene in different strains of Epstein-Barr virus. J Gen Virol 1994;75:95-100.
251. Gratama JW, Oosterveer MAP, Weimar W, et al. Detection of multiple 'ebnotypes' in individual Epstein-Barr virus carriers following lymphocyte transformation by virus derived from peripheral blood and oropharynx. J Gen Virol 1994;75:85-94.
252. Yao QY, Tierney RJ, Croom-Carter D, et al. Isolation of intertypic recombinants of Epstein-Barr virus from T-cell-immunocompromised individuals. J Virol 1996;70:4895-903.
253. Burrows JM, Khanna R, Sculley TB, et al. Identification of a naturally occurring recombinant Epstein-Barr virus isolate from new guinea that encodes both Type 1 and Type 2 nuclear antigen sequences. J Virol 1996;70:4829-33.
254. Schuster V, Seidenspinner S, Kreth HW. Detection of nuclear antigen 2 (EBNA2)-variant Epstein-Barr virus strain in two siblings with fatal lymphoproliferative disease. J Med Virol 1996;48:114-20.
255. Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 1995;332:19-25.
256. Kingma DW, Shad A, Tsokos M, et al. Epstein-Barr virus (EBV)-associated smooth-muscle tumor arising in a post-transplant patient treated successfully for two PT-EBV-associated large-cell lymphomas. Am J Surg Pathol 1996;20:1511-9.
257. Tornell J, Farzad S, Espander-Jansson A, et al. Expression of Epstein-Barr nuclear antigen 2 in kidney tubule cells induces tumors in transgenic mice. Oncogene 1996;12:1521-8.
258. Fanning E, Knippers R. Structure and function of simian virus 40 large tumor antigen. Annu Rev Biochem 1992;61:55-85.
259. Meggetto F, Brousset P, Selves J, et al. Reed-Sternberg cells and 'bystander' lymphocytes in lymph nodes affected by Hodgkin's disease are infected with different strains of Epstein-Barr virus. J Virol 1997;71:2547-9.
260. Hsieh JJD, Nofziger DE, Weinmaster G, et al. Epstein-Barr virus immortalization: notch2 interacts with CBF1 and blocks differentiation. J Virol 1997;71:1938-45.
261. Kirchmaier AL, Sugden B. Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus. J Virol 1997;71:1766-75.
262. Sing AP, Ambinder RF, Hong DJ, Jensen M, Batten W, Petersdorf E, Greenberg PD. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV + Hodgkin's disease. Blood 1997;89:1978-86.
263. Moss DJ, Schmidt C, Elliott S, Suhrbier A, Burrows S, Khanna R. Strategies involved in developing an effective vaccine for EBV-associated diseases. Adv Can Res 1996;69:213-45.